Stocks Health care TVRD

NASDAQ · Health care

Tvardi Therapeutics, Inc. (TVRD)

It posted a net loss of $26.1M. At June 30, 2026 it held $15.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.

Watch TVRD in 60 seconds

Follow TVRD

Free, no password. An email when TVRD files with the SEC.

Key facts about Tvardi Therapeutics, Inc.

Net worth

Tvardi Therapeutics, Inc. has a market value (market cap) of $18.8M at the latest share price, and shareholders' equity of $8.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Revenue and profit

In fiscal 2024 revenue was $7.1M (-66.0% year on year), with a net loss of $29.4M.

Cash flow

In fiscal 2025 operations used $23.5M of cash.

Latest report

The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR

Next earnings report

Tvardi Therapeutics, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.

What Tvardi Therapeutics, Inc. does

Tvardi Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker TVRD.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

Latest SEC filings

What Tvardi Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. August 14, 2026
   Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$0.69 versus -$1.00.
2. August 14, 2026
   Quarterly results 8-K
3. July 30, 2026
   Investor disclosure 8-K
4. July 17, 2026
   Other event 8-K
5. July 7, 2026
   Investor disclosure 8-K
6. June 11, 2026
   Shareholder vote results 8-K
7. May 8, 2026
   Form POS AM filing POS AM
8. May 8, 2026
   Quarterly report 10-Q · period to March 31, 2026Diluted EPS -$0.73 versus -$3.72.
9. May 8, 2026
   Quarterly results 8-K
10. May 1, 2026
    Shelf registration to sell securities S-3

Recent insider filings (Forms 3, 4 and 144): 10, the latest on June 11, 2026. Insider transactions on SEC

Insider trades

What the people running Tvardi Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns TVRD

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Latest filings below 5%: Ronald A. DePinho 4.5% (February 17, 2026); Samuel D. Tweardy 3.4% (August 5, 2025); Vifor (International) Ltd. 2.2% (April 16, 2025).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

No insider reported holdings on a Form 4 in the last 12 months.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about TVRD

What does Tvardi Therapeutics, Inc. do?

Tvardi Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as TVRD. Its shares trade on NASDAQ under the ticker TVRD.

What is Tvardi Therapeutics, Inc.'s net worth?

Tvardi Therapeutics, Inc. has a market value (market cap) of $18.8M at the latest share price, and shareholders' equity of $8.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Is Tvardi Therapeutics, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $26.1M.

When did Tvardi Therapeutics, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026.

When is Tvardi Therapeutics, Inc.'s next earnings report?

Tvardi Therapeutics, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.

Similar companies

Compare TVRD with

Compare TVRD with any company

Follow TVRD

Get an email when Tvardi Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow TVRD

Free, no password. An email when TVRD files with the SEC.

Where the numbers come from

Financial figures are the values Tvardi Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.